Tb535H is a humanized T-cell engager, trispecific antibody, directed against the 5T4/WAIF1 tumour antigen, a protein found on many different solid tumours and is thought to contribute to the spread of cancer cells. Tb535H recruits the patient’s T-cells –killer cells of the immune-system – and directs them to attack tumours. This highly targeted approach uses the patient’s own immune system to fight cancer. The WAIF1 antigen was discovered by scientists at the Cancer Research UK Manchester Institute. It could be a valuable target in many different cancer types, but the initial focus in this trial will be to treat cancers with high unmet-need. This includes thoracic cancers such as mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), for which survival remains very low, and renal cell carcinoma.
About Trisoma® technology
The Trisoma® technology enables the generation of multi-specific antibody products. This unique technology overcomes the key shortcomings of conventional mono- as well as of currently developed bi-specific antibody formats. With the Trisoma® technology, Biotecnol can engineer and assemble recombinant antibodies in a rational manner in order to design a chosen mechanism of action to address the killing of a specific tumour type.
About Chiome Bioscience, Inc.
Chiome Bioscience is a biotechnology company with its focus on discovery and development of antibody-based therapeutics in the disease area where high unmet medical needs exist, such like oncology, immunology, CNS, and inflammatory. It has several programs in discovery and preclinical stage in these fields. Chiome owns proprietary antibody generating technology named ADLib® System, together with currently available platforms. It was founded in 2005, and is listed on Tokyo stock exchange Mothers (code: 4583), and is located in Tokyo, Japan.
Biotecnol is developing innovative immune-function activating and immune-function modulation approaches for treating cancer. These approaches seek to recruit or to modulate the body’s own immune defenses such as T cells and NK cells to kill tumours. Biotecnol multi-specific antibody products are based on its proprietary Trisoma® platform, which are comprised of a variety of formats with key properties. Under the Trisoma® platform, Biotecnol has developed a novel format known as Targeted T-cell Engaging Agonistic Response Modifiers or iChecks. These products aim at improving tumour cell dependent T-cell or NK-cell activation. The iCheck formats are expected to achieve a more localized immune-function activation and obtain less or no systemic toxicity, whilst having an increased therapeutic index. These are potentially safer and more effective drugs for treating highly-heterogeneous and highly-aggressive solid tumours.
Biotecnol Press Release